Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1295-1295, Vol. 8, No. 6
A Double-Blind, Adjuvant-Controlled Trial of
Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen
(Remune) Monotherapy in Asymptomatic, HIV-1-Infected Thai
Subjects with CD4-Cell Counts of >300
Faculty of Science and Department of Biostatistics, Faculty of
Public Health, Mahidol University, Vajira Hospital,
Bangkok, Metropolitan Authority, and Pramongkutklao College of
Medicine, Bangkok, Khon Kaen University Hospital, Khon Kaen,
Songklanakarindh University, Songkla, and Chiang Mai University, Chiang
Mai, Thailand, and The Immune Response Corporation, Carlsbad,
California
Volume 7, no. 5, p. 728-733, 2000. The commercial affiliation,
equity interests, and patent-licensing arrangement of Dr.
Churdboonchart were not disclosed in the manuscript submittal letter.
Dr. Churdboonchart was associated with the Trinity Medical Group Co.,
Ltd., which was formed to sponsor the clinical trial of Remune in
Thailand through a collaborative and license agreement with the Immune Response Corporation, the maker of Remune.
1071-412X/01 DOI:
Copyright © 2001, American Society for Microbiology. All rights reserved.
AUTHOR'S CORRECTION
Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1295-1295, Vol. 8, No. 6
1071-412X/01 DOI:
Copyright © 2001, American Society for Microbiology. All rights reserved.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»